TY - JOUR
T1 - Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease
AU - Orrú, Christina D.
AU - Yuan, Jue
AU - Appleby, Brian S.
AU - Li, Baiya
AU - Li, Yu
AU - Winner, Dane
AU - Wang, Zerui
AU - Zhan, Yi An
AU - Rodgers, Mark
AU - Rarick, Jason
AU - Wyza, Robert E.
AU - Joshi, Tripti
AU - Wang, Gong Xian
AU - Cohen, Mark L.
AU - Zhang, Shulin
AU - Groveman, Bradley R.
AU - Petersen, Robert B.
AU - Ironside, James W.
AU - Quiñones-Mateu, Miguel E.
AU - Safar, Jiri G.
AU - Kong, Qingzhong
AU - Caughey, Byron
AU - Zou, Wen Quan
N1 - Publisher Copyright:
© 2017 The Authors.
PY - 2017/11/22
Y1 - 2017/11/22
N2 - Sporadic Creutzfeldt-Jakob disease (sCJD), the mostcommon human prion disease, is transmissible through iatrogenic routes due to abundant infectious prions [misfolded forms of the prion protein (PrPSc)] in the central nervous system (CNS). Some epidemiological studies have associated sCJD risk with non-CNS surgeries. We explored the potential prion seeding activity and infectivity of skin from sCJD patients. Autopsy or biopsy skin samples from 38 patients [21 sCJD, 2 variant CJD (vCJD), and 15 non-CJD] were analyzed by Western blotting and real-time quaking-induced conversion (RT-QuIC) for PrPSc. Skin samples from two patients were further examined for prion infectivity by bioassay using two lines of humanized transgenic mice. Western blotting revealed dermal PrPSc in one of five deceased sCJD patients and one of two vCJD patients. However, the more sensitive RT-QuIC assay detected prion seeding activity in skin from all 23 CJD decedents but not in skin from any non-CJD control individuals (with other neurological conditions or other diseases) during blinded testing. Although sCJD patient skin contained ∼103- to 105-fold lower prion seeding activity than did sCJD patient brain tissue, all 12 mice from two transgenic mouse lines inoculated with sCJD skin homogenates from two sCJD patients succumbed to prion disease within 564 days after inoculation. Our study demonstrates that the skin of sCJD patients contains both prion seeding activity and infectivity, which raises concerns about the potential for iatrogenic sCJD transmission via skin.
AB - Sporadic Creutzfeldt-Jakob disease (sCJD), the mostcommon human prion disease, is transmissible through iatrogenic routes due to abundant infectious prions [misfolded forms of the prion protein (PrPSc)] in the central nervous system (CNS). Some epidemiological studies have associated sCJD risk with non-CNS surgeries. We explored the potential prion seeding activity and infectivity of skin from sCJD patients. Autopsy or biopsy skin samples from 38 patients [21 sCJD, 2 variant CJD (vCJD), and 15 non-CJD] were analyzed by Western blotting and real-time quaking-induced conversion (RT-QuIC) for PrPSc. Skin samples from two patients were further examined for prion infectivity by bioassay using two lines of humanized transgenic mice. Western blotting revealed dermal PrPSc in one of five deceased sCJD patients and one of two vCJD patients. However, the more sensitive RT-QuIC assay detected prion seeding activity in skin from all 23 CJD decedents but not in skin from any non-CJD control individuals (with other neurological conditions or other diseases) during blinded testing. Although sCJD patient skin contained ∼103- to 105-fold lower prion seeding activity than did sCJD patient brain tissue, all 12 mice from two transgenic mouse lines inoculated with sCJD skin homogenates from two sCJD patients succumbed to prion disease within 564 days after inoculation. Our study demonstrates that the skin of sCJD patients contains both prion seeding activity and infectivity, which raises concerns about the potential for iatrogenic sCJD transmission via skin.
UR - http://www.scopus.com/inward/record.url?scp=85035056321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85035056321&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aam7785
DO - 10.1126/scitranslmed.aam7785
M3 - Article
C2 - 29167394
AN - SCOPUS:85035056321
SN - 1946-6234
VL - 9
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 417
M1 - eaam7785
ER -